Respiratory Tract Inflammatory Disorders - Pipeline Review - H1 2014






Published: March 2014 | Pages: 42 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘Respiratory Tract Inflammatory Disorders - Pipeline Review, H1 2014’, provides an overview of the Respiratory Tract Inflammatory Disorders’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Respiratory Tract Inflammatory Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Tract Inflammatory Disorders and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

  •  The report provides a snapshot of the global therapeutic landscape of Respiratory Tract Inflammatory Disorders 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Respiratory Tract Inflammatory Disorders and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Respiratory Tract Inflammatory Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Respiratory Tract Inflammatory Disorders pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 Reasons to buy 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Inflammatory Disorders 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding Respiratory Tract Inflammatory Disorders pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Table of Contents 

 Introduction 5 

 Global Markets Direct Report Coverage 5 

 Respiratory Tract Inflammatory Disorders Overview 6 

 Therapeutics Development 7 

 Pipeline Products for Respiratory Tract Inflammatory Disorders - Overview 7 

 Pipeline Products for Respiratory Tract Inflammatory Disorders - Comparative Analysis 8 

 Respiratory Tract Inflammatory Disorders - Therapeutics under Development by Companies 9 

 Respiratory Tract Inflammatory Disorders - Therapeutics under Investigation by Universities/Institutes 10 

 Respiratory Tract Inflammatory Disorders - Pipeline Products Glance 11 

 Late Stage Products 11 

 Early Stage Products 12 

 Respiratory Tract Inflammatory Disorders - Products under Development by Companies 13 

 Respiratory Tract Inflammatory Disorders - Products under Investigation by Universities/Institutes 14 

 Respiratory Tract Inflammatory Disorders - Companies Involved in Therapeutics Development 15 

 Merck & Co., Inc. 15 

 UCB S.A. 16 

 Verona Pharma Plc 17 

 GlycoMar Limited 18 

 Trino Therapeutics Ltd 19 

 Covigilance sro 20 

 Respiratory Tract Inflammatory Disorders - Therapeutics Assessment 21 

 Assessment by Monotherapy Products 21 

 Assessment by Target 22 

 Assessment by Mechanism of Action 24 

 Assessment by Route of Administration 26 

 Assessment by Molecule Type 28 

 Drug Profiles 30 

 COVXPB-21 - Drug Profile 30 

 Product Description 30 

 Mechanism of Action 30 

 R&D Progress 30 

 GLY-145 - Drug Profile 31 

 Product Description 31 

 Mechanism of Action 31 

 R&D Progress 31 

 PH-5 - Drug Profile 32 

 Product Description 32 

 Mechanism of Action 32 

 R&D Progress 32 

 Small Molecules to Inhibit Cells Expressing CD44 for Respiratory Tract Inflammatory Disorders - Drug Profile 33 

 Product Description 33 

 Mechanism of Action 33 

 R&D Progress 33 

 SPA-0355 - Drug Profile 34 

 Product Description 34 

 Mechanism of Action 34 

 R&D Progress 34 

 Inhaled Dissociated Steroid For Respiratory Disorders - Drug Profile 35 

 Product Description 35 

 Mechanism of Action 35 

 R&D Progress 35 

 NAIPs - Drug Profile 36 

 Product Description 36 

 Mechanism of Action 36 

 R&D Progress 36 

 GLY-079 - Drug Profile 37 

 Product Description 37 

 Mechanism of Action 37 

 R&D Progress 37 

 VR-942 - Drug Profile 38 

 Product Description 38 

 Mechanism of Action 38 

 R&D Progress 38 

 Respiratory Tract Inflammatory Disorders - Dormant Projects 39 

 Respiratory Tract Inflammatory Disorders - Product Development Milestones 40 

 Featured News & Press Releases 40 

 Jan 02, 2012: Orchid Pharma Reports Successful Completion Of Phase I Study Of OCID 2987 40 

 Appendix 41 

 Methodology 41 

 Coverage 41 

 Secondary Research 41 

 Primary Research 41 

 Expert Panel Validation 41 

 Contact Us 42 

 Disclaimer 42 

  

 List of Tables 

 Number of Products under Development for Respiratory Tract Inflammatory Disorders, H1 2014 7 

 Number of Products under Development for Respiratory Tract Inflammatory Disorders - Comparative Analysis, H1 2014 8 

 Number of Products under Development by Companies, H1 2014 9 

 Number of Products under Investigation by Universities/Institutes, H1 2014 10 

 Comparative Analysis by Late Stage Development, H1 2014 11 

 Comparative Analysis by Early Stage Development, H1 2014 12 

 Products under Development by Companies, H1 2014 13 

 Products under Investigation by Universities/Institutes, H1 2014 14 

 Respiratory Tract Inflammatory Disorders - Pipeline by Merck & Co., Inc., H1 2014 15 

 Respiratory Tract Inflammatory Disorders - Pipeline by UCB S.A., H1 2014 16 

 Respiratory Tract Inflammatory Disorders - Pipeline by Verona Pharma Plc, H1 2014 17 

 Respiratory Tract Inflammatory Disorders - Pipeline by GlycoMar Limited, H1 2014 18 

 Respiratory Tract Inflammatory Disorders - Pipeline by Trino Therapeutics Ltd, H1 2014 19 

 Respiratory Tract Inflammatory Disorders - Pipeline by Covigilance sro, H1 2014 20 

 Assessment by Monotherapy Products, H1 2014 21 

 Number of Products by Stage and Target, H1 2014 23 

 Number of Products by Stage and Mechanism of Action, H1 2014 25 

 Number of Products by Stage and Route of Administration, H1 2014 27 

 Number of Products by Stage and Molecule Type, H1 2014 29 

 Respiratory Tract Inflammatory Disorders - Dormant Projects, H1 2014 39 

  

 List of Figures 

 Number of Products under Development for Respiratory Tract Inflammatory Disorders, H1 2014 7 

 Number of Products under Development for Respiratory Tract Inflammatory Disorders - Comparative Analysis, H1 2014 8 

 Number of Products under Development by Companies, H1 2014 9 

 Comparative Analysis by Early Stage Products, H1 2014 12 

 Assessment by Monotherapy Products, H1 2014 21 

 Number of Products by Top 10 Target, H1 2014 22 

 Number of Products by Stage and Top 10 Target, H1 2014 23 

 Number of Products by Top 10 Mechanism of Action, H1 2014 24 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25 

 Number of Products by Top 10 Route of Administration, H1 2014 26 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 27 

 Number of Products by Top 10 Molecule Type, H1 2014 28 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 29 

  

 Companies Mentioned 

 Merck & Co., Inc. 

 UCB S.A. 

 Verona Pharma Plc 

 GlycoMar Limited 

 Trino Therapeutics Ltd 

 Covigilance sro